Toll-like receptor 2 (TLR2) heterodimer (TLR2 heterodimer)

Toll-like receptor 2 (TLR2) is a fundamental pattern recognition receptor (PRR) that functions as a heterodimer, primarily pairing with TLR1 or TLR6 to detect diverse pathogen-associated molecular patterns (PAMPs) (UniProt O60603). The TLR2/TLR1 heterodimer specifically recognizes triacylated lipopeptides from Gram-negative bacteria, while the TLR2/TLR6 heterodimer identifies diacylated lipopeptides from Gram-positive bacteria and mycoplasma (PubMed: 17588511). Upon activation, these complexes recruit the adapter protein MyD88, initiating a signaling cascade that activates NF-κB and mitogen-activated protein kinases (MAPKs), leading to the production of pro-inflammatory cytokines like TNF-α and IL-6 (PubMed: 25692144). In clinical contexts, TLR2-containing heterodimers are implicated in the pathogenesis of sepsis, ischemia-reperfusion injury, and chronic inflammatory diseases (PubMed: 21909101). Therapeutic interventions include monoclonal antibodies like Tomaralimab (OPN-305), which blocks TLR2 dimerization to prevent excessive inflammation, and synthetic agonists like Pam3CSK4 used in immunological research and vaccine development (DrugBank DB12836). However, targeting these receptors necessitates a balance between controlling inflammation and maintaining the host's ability to fight infections (PubMed: 23435337).

Other names

TLR2/1 complexTLR2/6 complexTLR2/10 complexCD282 heterodimerToll-like receptor 2/1 heterodimerToll-like receptor 2/6 heterodimer

Antagonists inhibit the formation or signaling of the TLR2/1 or TLR2/6 complexes to reduce pro-inflammatory cytokine production, while agonists stimulate these complexes to enhance innate immune responses or act as vaccine adjuvants.